Acelyrin's IL-17 inhibitor fails to hit primary endpoint in key study after splashy IPO

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Acelyrin said Monday that its lead drug izokibep failed to meet the primary endpoint in a Phase IIb/III trial in patients with hidradenitis suppurativa …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Acelyrin's IL-17 inhibitor fails to hit primary endpoint in key study after splashy IPO

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Ace­lyrin's IL-17 in­hibitor fails to hit pri­ma­ry end­point in key study af­ter splashy IPO

Senior Reporter

News Reporter

Sign up to read this article for free.

Acelyrin's IL-17 inhibitor fails to hit primary endpoint in key study after splashy IPO